Hepatocellular Carcinoma (Primary Hepatoma): Comprehensive Overview
Presentation
HCC typically presents in patients with chronic liver disease, most commonly cirrhosis, with a strong male predominance (4-8:1 ratio) and peak incidence between ages 50-60 years. 1, 2
Key Clinical Features to Identify:
- Symptoms of chronic liver disease: jaundice, ascites, hepatic encephalopathy, splenomegaly
- Risk factor assessment:
- Hepatitis B or C infection (HBV increases risk 100-fold in cirrhosis)
- Alcohol abuse (doubles risk when combined with HCV)
- Non-alcoholic fatty liver disease/metabolic dysfunction
- Genetic hemochromatosis
- Aflatoxin B1 exposure (in endemic areas)
- Performance status and nutritional state
- Portal hypertension signs: varices, hypertensive gastropathy 1
Critical pitfall: Any deterioration in liver function in a known cirrhotic patient should immediately raise suspicion for HCC 2. Most cases (75%) are multifocal at diagnosis 2.
Diagnosis
In cirrhotic patients with lesions >2 cm showing arterial hyperenhancement and venous/delayed phase washout on dynamic CT or MRI, HCC can be diagnosed without biopsy. 1, 3, 4
Diagnostic Algorithm:
For lesions detected on surveillance ultrasound:
Nodules <1 cm: Follow with ultrasound every 3-6 months 2
Nodules 1-2 cm: Investigate with at least two dynamic imaging studies (triphasic CT, contrast-enhanced MRI, or contrast-enhanced ultrasound) 2
- If typical vascular pattern on both studies → Diagnose as HCC
- If atypical → Biopsy
Nodules >2 cm in cirrhotic liver:
Essential Diagnostic Work-up:
Laboratory:
Imaging:
- Dynamic (multiphasic) CT or MRI for diagnosis and staging
- Chest CT in advanced disease
- Upper endoscopy to assess varices 1
Important caveat: Serum AFP has no role in the diagnostic algorithm for nodule characterization 4. The diagnosis relies on imaging characteristics, not tumor markers.
Treatment Options
Surgery (resection or transplantation) remains the only proven curative therapy, with local ablation as an alternative for very early disease. 3
Treatment Algorithm by Stage:
Very Early/Early Stage (BCLC 0-A):
1. Surgical Resection 1
- Indicated for:
- Non-cirrhotic liver (including fibrolamellar variant)
- Cirrhotic patients with single lesion, Child-Pugh A, no portal hypertension
- Postoperative mortality <5% when properly selected
- Contraindication: Clinically significant portal hypertension
2. Liver Transplantation 1
- Milan Criteria (gold standard):
- Single lesion ≤5 cm OR
- Up to 3 nodules ≤3 cm each
- Best for: Cirrhotic patients unsuitable for resection
- If waiting time >6 months: Bridge with resection, ablation, or TACE 1
3. Local Ablation 1
- Radiofrequency ablation (RFA):
- Preferred over PEI, especially for tumors >2 cm
- Maximum: 5 lesions, each ≤5 cm diameter
- Best for: Single nodule <2 cm (BCLC stage 0)
- Percutaneous ethanol injection (PEI):
- Best for peripheral lesions <3 cm 3
Critical point: Neo-adjuvant or adjuvant therapies are NOT recommended 1
Intermediate Stage (BCLC B):
Transarterial Chemoembolization (TACE) 1
- Indicated for: Multinodular asymptomatic tumors without vascular invasion or extrahepatic spread
- Requires: Excellent liver function
- Preferred technique: Doxorubicin-eluting beads to minimize systemic toxicity 1
- Do NOT combine with sorafenib outside clinical trials 1
Advanced Stage (BCLC C):
Sorafenib is the standard first-line systemic therapy for patients with well-preserved liver function (Child-Pugh A) 1
- Also indicated for intermediate stage progressing after TACE
- Upon progression/intolerance: Best supportive care or clinical trials 1
Explicitly NOT recommended 1:
- Systemic chemotherapy
- Tamoxifen
- Immunotherapy (note: this is from 2012 guidelines; newer immunotherapy combinations are now standard)
- Anti-androgens
- Somatostatin analogues
Radioembolization (Y-90) 1:
- May be competitive with sorafenib/TACE in select patients
- Best for: Prior TACE failure, excellent liver function, macrovascular invasion WITHOUT extrahepatic disease
End-Stage Disease:
Only symptomatic treatment for heavily impaired liver function or poor performance status 1
- External beam radiotherapy for painful bone metastases 1
Prevention
Universal hepatitis B vaccination at birth is the most effective primary prevention strategy. 1
Evidence-Based Prevention Measures:
Primary Prevention:
Secondary Prevention (Surveillance):
Six-monthly abdominal ultrasound is the standard surveillance method 1, 3, 2, 3
High-risk groups requiring surveillance 3:
- All cirrhotic patients with Child-Pugh A or B and non-HCC life expectancy >6 months
- Cirrhosis from any cause:
- HBV (especially with ongoing replication)
- HCV
- Genetic hemochromatosis
- Alcohol (in abstinent/compliant males)
- Primary biliary cirrhosis (males)
- Chronic HBV without cirrhosis in specific populations (family history, certain ethnic backgrounds)
Surveillance protocol 3, 2, 3:
- Ultrasound every 6 months
- AFP measurement (adjunctive, not diagnostic)
- Important caveat: Patients should understand implications of early diagnosis and lack of proven survival benefit from surveillance itself 3
Post-Treatment Monitoring
Dynamic CT or MRI every 3 months for the first 2 years, then every 6 months thereafter for patients who underwent curative treatment 1
Monitoring Protocol:
For curative treatments (resection/ablation/transplant) 1:
- Clinical evaluation for liver decompensation
- Dynamic CT/MRI every 3 months × 2 years
- Then surveillance every 6 months
For palliative treatments (TACE/sorafenib) 1:
- Clinical assessment for liver decompensation
- Dynamic CT/MRI every 2 months to guide therapy decisions
Response assessment 1:
- Use modified RECIST (mRECIST) criteria based on viable tumor (arterial enhancement)
- AFP may be helpful for non-measurable disease but should NOT be sole determinant 1
Critical point: Viable tumor is defined as contrast uptake in arterial phase on dynamic imaging 1